The effect of nimodipine and prednisolone on traumatic facial nerve injury treatment

Tolga Dölen¹, İrfan Kaygusuz¹, Nusret Akpolat², Hayrettin Cengiz Alpay¹, Erol Keleş¹,
Turgut Karlıdağ¹, Şinasi Yalçın¹, Koray Yüksel¹

¹Department of ORL, Faculty of Medicine, Fırat University, Elazığ, Turkey
²Department of Pathology, Faculty of Medicine, İnönü University, Malatya, Turkey
³Department of ORL, Faculty of Medicine, Istanbul Kemerburgaz University, Istanbul, Turkey

Abstract

Objective: To investigate the histopathological effect of nimodipine and prednisolone treatment on an animal model with peripheral facial nerve paralysis generated by clamping.

Methods: Twenty-eight New Zealand originated rabbits with facial nerve paralysis of the buccal branches generated by clamping were divided into four groups of seven each, administered with nimodipine, methylprednisolone and nimodipine-methylprednisolone combination throughout 21 days. The injured neural tissues were investigated histopathologically after treatment regarding perineural fibrosis, collagen degeneration, axonal degeneration, myelin degeneration, Schwann cell proliferation, normal myelin structure, and edema. The groups were compared with each other and with the control group.

Results: Statistically significant difference was determined between nimodipine and control groups regarding increased number of collagen fibers, myelin degeneration, axonal degeneration and myelin structure; between nimodipine and methylprednisolone groups, and between nimodipine and nimodipine-methylprednisolone combination groups regarding edema (p<0.05). Statistically significant data were also found between methylprednisolone and control groups in terms of increased number of collagen fibers, myelin degeneration, axonal degeneration and edema; between nimodipine-methylprednisolone combination and the control groups in terms of increased number of collagen fibers, myelin degeneration, axonal degeneration, normal myelin structure and edema (p<0.05).

Conclusion: Nimodipine and methylprednisolone both have positive effects on traumatic peripheral nerve paralysis with nerve integrity preserved whereas advantage of nimodipine over methylprednisolone cannot be suggested.

Keywords: Facial nerve paralysis, nimodipine, methylprednisolone.

Özet: Nimodipin ve prednizolonun travmatik fasiların nöral hasarı üzerine etkisi

Amaç: Çalışmanın amacı klempleme ile periferik fasilalı paralizisi oluşturan hayvan modellerinde nimodipin ve prednizolon tedavisinin histopatolojik etkisini araştırmaktır.

Yöntem: Bükkal sinir dallar klemple klempleme ile fasilalı paralizisi oluşturan 28 Yeni Zelanda kökenli tavşan, yediflerlik 4 gruba ayrıldı ve her bir gruba 21 gün boyunca nimodipin, metilprednizolon ve nimodipin-metilprednizolon kombinasyonu uygulandı. Tedavi sonrası nöral hasar dokuları histopatolojik olarak perineural fibrozis, kollajen liflerde artışı, miyelin dejenerasyonu, aksonal dejenerasyon, Schwann hücre proliferasyonu, normal miyelin yapısı ve ödem açısı deneysel olarak incelendi. Gruplar birbirleriyle ve kontrol grubuyla karşılaştırıldı.

Bulgular: Kollajen liflerde artışı, miyelin dejenerasyonu, aksonal dejenerasyon ve miyelin yapısı açısından nimodipin ve kontrol grubu arasında; nimodipin ve metilprednizolon grubu arasında; nimodipin ve metilprednizolon kombinasyonu ile kontrol grubu arasında istatistiksel olarak anlamalı farklılıklar belirlendi (p<0.05). Metilprednizolon grubu ile kontrol grubu arasında kollajen liflerde artış, miyelin dejenerasyonu, aksonal dejenerasyon ve ödem; nimodipin-ve metilprednizolon kombinasyonu ile kontrol grubu arasında da kollajen liflerde artış, miyelin dejenerasyonu, aksonal dejenerasyon ve normale miyelin yapısı ve ödem açısından istatistiksel olarak anlamalı farklılıklar saptandı (p<0.05).


Anahtar sözcükler: Fasial paralizi, nimodipin, metilprednizolon.
The mimic muscles on our face reflect not only our genetic and physical properties but also our mood expression, therefore, helping other people to understand our feelings. Patients with facial nerve dysfunction suffer from some functional and emotional problems. In order to prevent these issues and regain facial nerve functions, alternative methods of nerve recovery are needed to be developed in addition to surgical treatment.

Recently, there has been a remarkable achievement in the treatment of peripheral nerve lesions and constructing related defects after increased anatomic and histopathological knowledge together with the improvement of surgical techniques to overcome nerve injury due to trauma, surgical intervention, tumors, compression and inflammatory processes. Markedly increased microsurgical techniques and improved histological and immunohistochemical methods have contributed to success in peripheral nerve injury treatment. In the treatment of traumatic peripheral facial nerve paralysis, substances such as neurotrophic factors, steroids, hormones and varying chemicals are also used for the purpose of nerve recovery in addition to many surgical techniques depending on the type of tissue damage.

One of the chemical agents under investigation today is a 1,4 dihydropyridine derivative L-type voltage-dependent calcium channel antagonist, known as nimodipine. Calcium ions have key roles in depolarization, growth, excitability, aging, learning and cell proliferation, therefore, maintaining neural plasticity. During peripheral nerve injury, permeability dysfunction of plasma membrane results in intracellular calcium accumulation due to electrochemical gradient difference. This intracellular calcium triggers a chain of periodic chemical reactions leading to cell death.

In this study, we have developed a hypothesis of a chemical agent which prevents excessive calcium transition into the cell, with an assumption of having a role in diminishing mechanically induced nerve injury, therefore improving tissue recovery. For this purpose, we investigated the effects of nimodipine and methylprednisolone treatments in an animal model of peripheral facial nerve paralysis.

Materials and Methods

This study is performed on 28 New Zealand originated rabbits weighing 1200–1300 grams each, with the approval of Animal Experiments Ethics Committee, and the materials are supplied by Scientific Search Project Unit of our University (Project No. TF05.11) All of the subjects were evaluated in terms of facial functions and those with no abnormalities were included. Symmetrical movements of mustache during chewing and presence of blinking reflex of the eyes during positive air pressure applied to the face by using a syringe were accepted as criteria of normal function.

All subjects underwent same surgical procedures by the same surgeon. They were given anesthesia by administering 10 mg/kg xylazine hydrochloride (Rompun®, Bayer AG, Leverkusen, Germany) and 50 mg/kg ketamine hydrochloride (Ketalar®, Eczacıbaşı Drug, Istanbul, Turkey) and the area over facial nerve route on their faces were shaved before the intervention. A 2 cm long horizontal incision was made infraorbital parallel to the mandible. The skin and subcutaneous tissue were dissected, and the buccal branch of the facial nerve was identified with the help of nerve stimulator in each case. Marked area of the nerve was clipped by Yaşargil-Phynox Aneurysm Clips (Aesculap AG, Tuttlingen, Germany) with a standard closure pressure of 188 g/cm² and tolerance pressure of 162–198 g/cm² lasting for one-minute compression (Fig. 1). Clipped area was pointed out by a suture applied to the underlying muscle tissue 5-0 silk (Ethicon Deutschland, Norderstedt, Germany) and the incision is closed at the end of clipping time by using 4-0 silk suture (Ethicon Deutschland, Norderstedt, Germany). 20–40 mg/kg of cefazoline sodium (Sefazol Fık®, Mustafa Nevzat, Istanbul, Turkey) was administered to each subject prophylactically through intramuscular route, 1 hour before and after the surgical procedure.

Fig. 1. Clamping the buccal branch of facial nerve with aneurysm clips.
28 subjects were divided into four randomized groups including seven of each and given medical treatment specified below for 21 days:

- **Group I (Nimodipine group):** 0.5 mg/kg/day nimodipine (Nimotop®, Bayer AG, Leverkusen, Germany), intraperitoneally
- **Group II (Methylprednisolone group):** 1 mg/kg/day methylprednisolone (Prednol-L®, Mustafa Nevzat, Istanbul, Turkey), intramuscularly
- **Group III (Nimodipine-methylprednisolone group):** 0.5 mg/kg/day nimodipine intraperitoneally and 1 mg/kg/day methylprednisolone intramuscularly
- **Group IV (Control group):** 1 cc of saline solution intramuscularly

A re-incision was made over preexisting incision site on 21st day postoperatively. The destroyed segment of the buccal branch of the nerve was found as it was pointed out before, dissected from surrounding tissue and excised 5 mm proximally and 5 mm distally.

Excised specimens were fixed in 10% glutaraldehyde and cross-sectioned into vertical and horizontal slices with a 1.5 μ thickness of each by ultratome III glass knives (Shandon Finesse, Fisher Scientific, Leicester, UK). Slices were stained with Masson trichrome and hematoxylin–eosin (HE) and examined under the light microscope under ×40, 100, 200 and 1000 magnifications (Olympus, BX51, Tokyo, Japan).

Perineural fibrosis, increased number of collagen fibers, myelin degeneration, axonal degeneration, Schwann cell proliferation, normal structure of myelin and edema were studied on half thin tissue sections and graded as: none: - (0), mild: + (1), moderate: ++ (2), severe: +++ (3). Eyepiece graticule (ocular micrometer, 1x1 mm sized with 100 equal squares) attached to Olympus light microscope was used for counting. 4 areas of 4 cross-sections of each subject (×40, 100, 200, 1000 magnification) were counted and the averages of 4 areas for each group were calculated.

Histopathological data were collected by subject follow-up forms, SPSS 11.5 (SPSS Inc., Chicago, IL, USA) program was used for statistical analysis and Mann-Whitney U test was used for group comparison. The statistical significance level was determined as 0.05.

**Results**

Histopathological grading of parameters for each group is shown in Table 1. As given in details, perineural fibrosis was not detected in any group except for 1 subject of the control group. Therefore, no statistically significant difference was found (p>0.05) (Table 2).

Increased number of collagen fibers was mostly seen in control group and less in Group III. Statistically significant data were found between Groups I, II and III when compared with the control group (Group IV), no significance was found between the control group and Groups I, II and III when compared with each other (p>0.05) (Table 2; Figs. 3 and 4).

In terms of Schwann cell proliferation, despite higher histopathological scores were detected in Groups I, II and III when compared with the control group (Group IV), no significance was found between the control group and Groups I, II and III when compared with each other (p>0.05) (Table 2; Figs. 2, 3 and 4).

The normal myelin structure was mostly seen in Group III followed by Groups I, II and IV, respectively. Significant data were found between Groups I and III (p<0.05), whereas no significant data were found between Group II and the control group (Group IV) and between Groups I, II and III when compared with each other (p>0.05) (Table 2; Fig. 6).

Edema was found at least in Group III, followed by Groups II, I and IV, respectively. No statistically significant data were found between Groups II and III (p>0.05), whereas the data collected from comparisons between Groups II–III (together) and I and between Groups II–III (together) and IV were found to be significant (p<0.05). Also, no significance was found between Groups I and IV (p>0.05) (Table 2; Fig. 7).

**Discussion**

Facial paralysis is a clinical issue, which occurs due to a partial or complete dysfunction of the facial nerve, mostly seen as a result of trauma, surgical intervention, tumors, compression, inflammation or infection. Trauma is the second most common cause of peripheral facial nerve paralysis, following Bell’s palsy. Facial nerve can be traumatized by temporal bone fractures, gunshot, surgery (tympanomastoid surgery, acoustic neuroma surgery, parotid surgery) and penetrating laceration of the face.
The treatment varies according to the type of the injury and clinical manifestation. Many medical treatments have been suggested for years to improve neural function and shorten recovery period, and investigations still go on. Today, steroids are the most preferred agents as their anti-inflammatory and immunosuppressive effects are known to play a key role in the treatment of nerve injury, particularly in Bell’s palsy.

Lieberman et al. demonstrated a significant effect of low-dose steroids on the recovery of neural function by studying on rats with clamping induced nerve injury. Sekiya et al. investigated the effect of methylprednisolone on cochlear nerve degeneration created by clamping and suggested that it might prevent neural damage. Edema reducing the effect of methylprednisolone is believed to play an important role. In concordance with the literature, we observed remarkable antiedema effect in groups of which methylprednisolone was administered.

Vita et al. investigated neural regeneration rate in subjects with sciatic nerves clamped, examined from the point of injury to tibialis anterior and concluded that the group which received steroid had shown slightly significant improvement as compared to the control group. In our study, we observed less increase in the number of collagen fibers, less axonal and myelin degeneration and also less edema in the groups which were administered methylprednisolone (Groups II and III). In addition to those parameters, we found significant increment in a normal myelin structure in the nimodipine-methylprednisolone group (Group III). All these results suggest that steroids have a positive effect on traumatic nerve injury in those

<table>
<thead>
<tr>
<th></th>
<th>Subject number</th>
<th>Perineural fibrosis</th>
<th>Increase in the number of collagen fibers</th>
<th>Myelin degeneration</th>
<th>Axonal degeneration</th>
<th>Schwann cell proliferation</th>
<th>Normal myelin structure</th>
<th>Edema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nimodipine group</td>
<td>1</td>
<td>-</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>-</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>-</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>-</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Methylprednisolone group</td>
<td>1</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Nimodipine – methylprednisolone group</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>-</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Control group</td>
<td>1</td>
<td>-</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>-</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>+</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>-</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>-</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>-</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>-</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+++</td>
</tr>
</tbody>
</table>

None: - (0), mild: + (1), moderate: ++ (2), severe: +++ (3)
with nerve integrity preserved, as in concordance with the literature.

Despite these facts, the effect of corticosteroids on traumatic nerve injury recovery could not be thoroughly revealed. On the other hand, there are some reports about corticosteroids which emphasize their worsening effects on wound healing. [19–21] Karldağ et al. [22] found no effect of methylprednisolone on recovery after cutting and suturing of the facial nerve. In our study, we observed no Schwann cell proliferation and no increase in the number of the normal myelin structure, whereas we noticed an increase in myelin when administered in combination with nimodipine.

For the first time, Van der Zee et al. investigated the effect of nimodipine on peripheral nerve injury and

<table>
<thead>
<tr>
<th>Groups compared</th>
<th>Perineural fibrosis</th>
<th>Increase in the number of collagen fibers</th>
<th>Myelin degeneration</th>
<th>Axonal degeneration</th>
<th>Schwann cell proliferation</th>
<th>Normal myelin structure</th>
<th>Edema</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nimodipine group</td>
<td>Control group</td>
<td>.317</td>
<td>.030</td>
<td>.002</td>
<td>.002</td>
<td>.775</td>
<td>.015</td>
</tr>
<tr>
<td>Nimodipine group</td>
<td>Methylprednisolone group</td>
<td>1.000</td>
<td>.298</td>
<td>.606</td>
<td>.606</td>
<td>1.000</td>
<td>.298</td>
</tr>
<tr>
<td>Nimodipine group</td>
<td>Nimodipine-methylprednisolone group</td>
<td>1.000</td>
<td>.225</td>
<td>.591</td>
<td>.591</td>
<td>.674</td>
<td>.591</td>
</tr>
<tr>
<td>Methylprednisolone group</td>
<td>Control group</td>
<td>.317</td>
<td>.006</td>
<td>.002</td>
<td>.002</td>
<td>.775</td>
<td>.054</td>
</tr>
<tr>
<td>Methylprednisolone group</td>
<td>Nimodipine-methylprednisolone group</td>
<td>1.000</td>
<td>.705</td>
<td>.298</td>
<td>.298</td>
<td>.674</td>
<td>.122</td>
</tr>
<tr>
<td>Methylprednisolone group</td>
<td>Methylprednisolone group</td>
<td>.317</td>
<td>.007</td>
<td>.001</td>
<td>.001</td>
<td>.424</td>
<td>.006</td>
</tr>
</tbody>
</table>

Mann-Whitney U test

![Fig. 2](image1.png) The increase in the number of collagen fibers in nimodipine group (x200 HE).

![Fig. 3](image2.png) Myelin degeneration in methylprednisolone group (x200 HE).

![Fig. 4](image3.png) Axonal degeneration in the control group (x200 HE).
reported a corrective effect on neuromuscular functions of rat sciatic nerve. Angelov et al. reported that nimodipine administration after cutting and suturing of facial nerve had improved the axonal regeneration, had stimulated nerve healing and had reduced the hyper-innervation possibility. Our study supported the idea of reducing the effect of nimodipine on axonal and myelin degeneration.

Mattsson et al. underlined the importance of nerve surveillance on functional recovery after neural injury. For this purpose, they created facial nerve injury by cutting down subjects at the level of the middle cranial fossa and repaired them immediately, administered nimodipine and noticed that the number of surviving neurons in facial nerve motor nuclei was significantly high at the first month. In another study, Mattsson et al. created the intracranial nerve injury by crushing this time and reported that nimodipine had not much effect on motor nucleus cell loss (%13), but had stimulated axonal and myelin growth and improved functional recovery. In our study, we made a crushing type injury by compressing the nerve, and we detected decreased rates of axonal and myelin degeneration and increased normal myelin structure in nimodipine and nimodipine-methylprednisolone groups. Despite the fact that the increase in normal myelin structure in nimodipine group compared to the control group suggests the efficacy of nimodipine on nerve regeneration, it has no superiority over methylprednisolone regarding statistically significant difference.

Scheller et al. administered oral nimodipine in a group of patients with facial paralysis after maxillofacial surgery and graded the clinical manifestation by House-Brackmann scale. They indicated a lower duration of recovery period compared to the control group. In various studies, nimodipine used in the treatment of laryngeal nerve injury is shown to accelerate recovery period, and this is supported by objective measurements (EMG).

Pointillart et al. defined the therapeutic effect of 1-week nimodipine administration on spinal cord injury by increasing blood flow. He stated significant improvement in neurologic signs after administering methylprednisolone and nimodipine to 100 patients with spinal cord injury in

Fig. 5. Schwann cell proliferation in nimodipine group (×200 HE).

Fig. 6. Normal myelin structure in nimodipine-methylprednisolone group (×200 HE).

Fig. 7. Edema in nimodipine group (×200 HE).
The effect of nimodipine and prednisolone on traumatic facial nerve injury treatment

acute phase but found no difference between two groups.[13] Our study showed that nimodipine and methylprednisolone improved nerve regeneration, methylprednisolone had a superior effect on edema, and there was no significant difference in other parameters. Regarding normal myelin structure, we found remarkable increment in nimodipine group, but there was no evidence on the superiority over methylprednisolone.

**Conclusion**

As a conclusion, evidence obtained from clinical trials suggests that nimodipine, a calcium-channel blocker, improves functional recovery after nerve injury. Our study also demonstrated the accelerating effect of nimodipine on neural tissue healing, but we could not prove any superior effect of nimodipine over methylprednisolone. This result correlates with previous studies in the literature. Further studies should be performed to reinforce these results by using other objective methods such as EMG together with histopathological examination.

**Conflict of Interest:** No conflicts declared.

**References**


